Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
31 Outubro 2023 - 9:05AM
Business Wire
Seamless ordering and receipt of genomic test results directly
in patient records streamlines clinician access to precision
medicine tools
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, and Flatiron Health, a leading healthtech company
dedicated to expanding the possibilities of point of care solutions
in oncology and closing the gap between research and care, today
announced an initiative to integrate Guardant’s comprehensive
genomic profiling tests within Flatiron’s OncoEMR®, a leading
cloud-based electronic medical record (EMR) tool.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231031158337/en/
The integration simplifies access to critical data that informs
patient care decisions for over 2,000 clinicians within the
Flatiron network, which includes more than 800 community-based
cancer care locations across the U.S. Users can easily submit
Guardant Health test orders, track real-time status updates, and
receive the test results directly in the patient record, via the
Molecular Profiling Integration on the OncoEMR platform. This
streamlines workflows for physicians and saves time in the ordering
process. Clinicians use the test results to help select the best
treatment for patients with advanced cancer and monitor for
recurrence in patients with early-stage cancer.
“Genomic profiling provides critical data that helps oncologists
make timely and informed decisions about personalized treatment
plans for their patients,” said Chris Freeman, Guardant Health
chief commercial officer. “This integration with the OncoEMR
platform, which reaches almost 40 percent of U.S. community
oncologists, will simplify access to our tests and enable a
significant step forward in our mission to conquer cancer with
data.”
The companies beta-tested the integration at multiple oncology
practice sites across the U.S. earlier this year and saw >75%
utilization of the integration vs. traditional ordering workflows.
Guardant Health and Flatiron Health plan to roll the integration
out to the entire OncoEMR network over the next several months.
Practices in the network will have access to Guardant Health’s
entire portfolio of advanced blood and tissue tests for early- and
advanced-stage cancer through the Molecular Profiling
Integration.
“By offering integrated test ordering and reporting for Guardant
Health’s genomic profiling tests within OncoEMR, we are enabling
oncologists with the tools they need to further expand
possibilities at the point of care," said James Hamrick, MD, MPH,
Vice President, Clinical Oncology at Flatiron Health. “The
integration gives oncologists convenient access to the information
they need to practice precision medicine, contributing to better
patient outcomes, more time with patients, and a better care
experience for physicians and their patients.”
Guardant Health tests are also available through other EMR/EHR
systems that reach oncology practices in community and academic
settings.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping every person live a life free from cancer. Founded in
2012, Guardant is transforming cancer care by providing critical
insights into what drives the disease through its advanced blood
and tissue tests, real-world data and AI analytics. Guardant tests
help improve patient outcomes across all stages of cancer,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn and X
(Twitter).
About Flatiron Health
Flatiron Health is a healthtech company expanding the
possibilities for point of care solutions in oncology and using
data for good to power smarter care for every person with cancer.
Through machine learning and AI, real-world evidence, and
breakthroughs in clinical trials, we continue to transform
patients’ real-life experiences into knowledge and create a more
modern, connected oncology ecosystem. Flatiron Health is an
independent affiliate of the Roche Group. Flatiron.com
@FlatironHealth
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2022, and any
current and periodic reports filed with or furnished to the
Securities and Exchange Commission thereafter. The forward-looking
statements in this press release are based on information available
to Guardant Health as of the date hereof, and Guardant Health
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Guardant Health’s views
as of any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031158337/en/
Guardant Health Investor Contact:
investors@guardanthealth.com
Guardant Health Media Contact: Michael Weist
press@guardanthealth.com +1 650-647-3643
Flatiron Health Media Contact: Nina Toor
nina.toor@flatiron.com
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024